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A series of gold(I)-monophosphole complexes have been synthesized and characterized.
The introduction of a nitrogen moiety in the complex structure was envisioned either by
choosing the bis(triﬂuoromethanesulfonyl)imidate ligand as the X-ligand or by preparing a
new pyrrolidinophosphole ligand as the L-ligand. All the complexes have been evaluated
in vitro for their antimalarial activity. These goldephosphole complexes showed moderate
activities with IC50 values ranging from 9.7 to 24 mM against Plasmodium falciparum
chloroquine-resistant strains.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.r é s u m é
Une premiere serie de complexes d'or(I) [(L)Au(X)] portant un ligand monophosphole
comme ligand L et un ligand chlorure comme ligand X a ete synthetisee. Puis l'introduction
d'une fonction azotee dans la structure du complexe a ete envisagee, soit en utilisant le
ligand bis(triﬂuoromethanesulfonyl)imidate comme ligand X, soit en preparant un ligand
pyrrolidinophosphole comme ligand L. Tous les complexes ont ete caracterises et evalues
in vitro pour leur activite antipaludique. Ces complexes or-phosphole se sont reveles
moderement actifs sur des souches de Plasmodium falciparum resistantes a la chloroquine
avec des CI50 comprises entre 9,7 et 24 mM.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.1. Introduction
Malaria remains the most important parasitic disease
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K. Fourmy et al. / C. R. Chimie xxx (2016) 1e62permanent and urgent need to develop new chemical
compounds with original mechanisms of actions to
circumvent the drug resistance.
Inspired by the anti-cancer activity of cis-platin, a large
number of metal-based compounds have been investigated
for their medicinal activities [2] in particular for the treat-
ment of malaria [3]. Among the metal-based therapeutic
compounds, gold complexes have gained more attention in
the search of anti-cancer [4,5] or antimicrobial [6] agents.
Based on the clinical use of auranoﬁn, a thiolate-
phosphine gold(I) complex, for the treatment of arthritis,
the search of a gold(I) complex as a therapeutic compound
can be envisioned from a toxicological point of view [7].
MoreoverMessori and coll. reported in 2008 that auranoﬁn
exhibited promising antimalarial activity with an IC50 of
142 nM on the Plasmodium falciparum 3D7 strain [8].
Recent computational studies suggested that a thioredoxin
reductase of P. falciparum (PfTR) could be the target of
auranoﬁn and that the triethylphosphine-gold was the
active therapeutic agent, with the tetraacetylthioglucose
ligand being excreted in vivo [9]. Varying the structure of
the phosphine ligand should therefore modulate the bio-
logical activity of the complex.
Various ligands have been investigated in the search of a
gold(I) complex showing potential antimalarial activity.
Navarro et al. reported the preparation of gold(I) complexes
bearing chloroquine as an N-donor ligand [10e12], which
showed improved efﬁcacy against chloroquine-resistant
strains of P. falciparum with respect to chloroquine. How-
ever, gold complexes of the ferrocenyl-derivative of chlo-
roquine [13] exhibited an antagonistic effect on the overall
efﬁciency, which indicates that the quinoline moiety re-
mains the pharmacophore of these compounds. Ylidene-
amines were also evaluated as N-donor ligands by Cronje
and coll [14]: the corresponding gold(I) complexes exhibit
moderate activity against P. falciparum with IC50 ranging
from 6.9 to 8.5 mM on the 3D7 strain. C-donor ligands were
exempliﬁed by Hemmert and coll. describing the prepara-
tion of gold(I) complexes based on bis(N-heterocyclic car-
bene) ligands [15]. These complexes showed a weak
activity against P. falciparum (IC50 above 15 mM on the
FcM29-Cameroon strain) except when a pendant quinoline
or bipyridine ligandwas added to the NHC structure (IC50 of
1.1 and 0.33 mM, respectively). Gold(I) alkynyl complexes
were also proposed and evaluated against 3D7 or K1 P.
falciparum strains with IC50 in the 7.2e23.6 mM range [16].
Moderate antiplasmodial activities were also reported by
Chibale and coll [17] with gold (I) complexes based on
thiosemicarbazone ligands acting as S-donor ligands (IC50
of 2.0e6.9 mM against D10 or W2 strains). Finally, data
concerning gold(I) complexes bearing P-donor ligands can
also be found in the literature [18]. [Au(PEt)3Cl] [8] has an
IC50 of 2.1 mM on the P. falciparum strain 3D7 [8], while
gold(I) complexes bearing 1,10-bis(diphenylphosphine)
metallocene ligands [19] have IC50 in the 1.8e4.2 mM range
on the W2 strain [19].
On the other hand, Reau and Davioud-Charvet reported
the preparation and the biological evaluation of gold(I)
phosphole complexes as inhibitors of human glutathione
reductase and thioredoxin reductase [20e22]. Given the
putative key-role of the antioxidant enzyme thioredoxinPlease cite this article in press as: K. Fourmy, et al., Gold(I) comp
activity, Comptes Rendus Chimie (2016), http://dx.doi.org/10.1016reductase PfTR in P. falciparum metabolism [9], gold(I)
phosphole complexes should therefore be explored as
antimalarial agents.
Following our report on the synthesis of gold(I) com-
plexes bearing monophosphole ligands and their evalua-
tion as catalysts for enyne cycloisomerisation [23], we
report here the synthesis of new gold(I) monophosphole
complexes and the evaluation of their in vitro anti-
plasmodial activity.2. Results and discussion
2.1. Synthesis and characterization of gold(I) phosphole
complexes
Gold(I) complexes 1e4 (Fig. 1) bearing phenyl-
substituted phosphole ligands TMP L1, DBP L2, TPP L3
and DMP L4 respectively were prepared under mild con-
ditions using [Au(SMe2)Cl] as the precursor, as previously
described [23]. These complexes were obtained in good
yields and were isolated as air- and moisture-stable solids,
except for [Au(DMP)Cl] 4.
In order to study the inﬂuence of the X-ligand on the
biological activity of the complex, the phosphole gold(I)
complex 5 (Fig. 1), analogous to complex 3 and bearing a
bis(triﬂuoromethanesulfonyl)imidate ligand instead of the
chloride one, was also prepared.
The procedure described by Gagosz and coll [24] was
followed and the spectroscopic data were in agreement
with those previously reported.
Suitable single crystals of complex 5 were grown from
diffusion of pentane into a dichloromethane solution and
the molecular structure has been established by X-ray
diffraction studies (Fig. 2). Crystal data conﬁrm that
[Au(TPP)NTf2] 5 is in a slightly distorted linear geometry,
with an AueP distance similar to that observed for [Au(TPP)
Cl] 3 (Au(1)eP(1) 2.2241(6)) [23]. As expected, the AueN
distance is smaller than the AueCl distance in [Au(TPP)Cl] 3
(Au(1)eCl(1) 2.2817(6)) [23] but consistent with the AueN
distances observed in [Au(PPh3)NTf2] (Au(1)eN(1)
2.101(2)) [24] or in its derivative [Au(PPh3)NTfR] recently
developed by Newcombe et al. (Au(1)eN(1) 2.084(5)) [25].
Then, the introduction of an amine moiety on the
phosphole skeletonwas envisioned to increase the number
of H-bond acceptors in the compound. Following the syn-
thetic route we described in 2002 [26], we prepared a new
pyrrolidinophosphole ligand and the corresponding gold(I)
complex 6 (Scheme 1). 1-Cyano-2,3,4,5-tetrame
thylphosphole 6a was easily obtained from TMP L1
through the reductive cleavage of the phosphorus-phenyl
bond with an excess of metallic lithium followed by the
addition of BrCN after the neutralisation of PhLi using AlCl3
(Scheme 1). The pyrrolidinophosphole ligand L6 was then
prepared from the crude cyanophosphole 6a and the pre-
formed amide salt 6c, obtained by action of n-BuLi on (R)-2-
(diphenylmethyl)pyrrolidine 6b (Scheme 1). The new
gold(I) pyrrolidinophosphole complex 6 was ﬁnally pre-
pared using [Au(SMe2)Cl] as the precursor under mild
conditions: a white air-stable powder was obtained in a
48% yield from the cyanophosphole precursor.lexes bearing phosphole ligands: Synthesis and antimalarial
/j.crci.2016.06.008
Fig. 1. Phosphole ligands L1eL4 and their gold(I) complexes 1e5.
K. Fourmy et al. / C. R. Chimie xxx (2016) 1e6 3Complex 6 was fully characterized by spectroscopic
techniques. In comparison with the 31P chemical shift of
[Au(TMP)Cl] 1 (d ¼ 42.8, s, CD2Cl2) [23] a downﬁeld shift
was observed for complex 6 (d ¼ 79.6, s, CDCl3) as expectedFig. 2. Ortep plot of 5. Thermal ellipsoids are drawn at the 50% probability level, and
and angles (deg) with estimated standard deviations: Au(1)eP(1) 2.2282(4), Au(1)e
Please cite this article in press as: K. Fourmy, et al., Gold(I) comp
activity, Comptes Rendus Chimie (2016), http://dx.doi.org/10.1016since the pyrrolidinophosphole ligand L6 is a more electron
rich P-donor ligand than the corresponding TMP L1. This
31P NMR chemical shift higher than 70 ppm is also
consistent with those observed by Bella et al. [27] or Zhangthe hydrogen atoms have been omitted for clarity. Selected bond lengths (Å)
N(1) 2.1053(12), N(1)eAu(1)eP(1) 173.20(4), and C(4)eP(1)eC(1) 94.00(7).
lexes bearing phosphole ligands: Synthesis and antimalarial
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K. Fourmy et al. / C. R. Chimie xxx (2016) 1e64et al. [28] for a phosphorus atom in a similar R1R2NePeAu
environment.
The molecular structure of 6 has been established by X-
ray diffraction studies (Fig. 3) on suitable single crystals
grown from diffusion of pentane into a dichloromethane
solution of the complex. Complex 6 exhibits a linear ge-
ometry (PeAueCl 178.24(2)) with the pyrrolidinophosp-
hole acting as a P-donor monodentate ligand. The AueP
and AueCl distances compare well with those observed for
[Au(TMP)Cl] [23] 1 (Au(1)eP(1) 2.2241(12), Au(1)eCl(1)
2.2854(13)), indicating that the introduction of the amino
moiety does not signiﬁcantly change the structural fea-
tures of the gold environment. The NeP distance is com-
parable to that observed in platinum-complexes bearing
aminophosphole ligands (1.652e1.666) [29] and smaller
than that observed in a gold complex bearing an amino-
diphenylphosphine ligand (1.679) [30].Fig. 3. Ortep plot of 6. Thermal ellipsoids are drawn at the 50% probability
level, and the hydrogen atoms have been omitted for clarity. Selected bond
lengths (Å) and angles (deg) with estimated standard deviations: Au(1)
eP(1) 2.2278(5), Au(1)eCl(1) 2.3012(6), N(1)eP(1) 1.6577(17), P(1)eAu(1)
eCl(1) 178.24(2), and N(1)eP(1)eAu(1) 113.16(6).2.2. In vitro antimalarial activity
Complexes 1e6 were tested against the chloroquine-
resistant P. falciparum strains FcM29-Cameroon (IC50 of
chloroquine (CQ) ¼ 494 nM; of artemisinin (ART) ¼
12.7 nM) or FcB1-Colombia (IC50 of CQ ¼ 187 nM; of
ART ¼ 5 nM) and compared to the commercially available
phosphine gold(I) complex [Au(PPh3)Cl]. The results of
these in vitro antiplasmodial tests are presented in Table 1.
All the gold(I) complexes 1e4 bearing a monophosphole
ligand as the L-ligand and a chloride ligand as the X-ligand
showedmoderate activity with IC50 values between 9.7 and
24 mM which are several orders of magnitude higher than
that observed for CQ itself (0.5 mM). No correlation could be
established between the biological activity of the complex
and the electronic (s-donor ability) or steric (%VBur)
properties of the corresponding ligand [23] and no
phosphole gold(I) complexes 1e4 permitted to increase the
activity of their phosphine counterpart [Au(PPh3)Cl] (IC50
7.9 mM).
According to these ﬁrst results, pharmaco-modulations
of the gold(I) phosphole complexes were attempted to in-
crease the antiplasmodial activity. Moreover, in order to in-
crease the stability of the complexes, their solubility in a
physiological medium and their potential biocompatibility,Scheme 1. Synthesis of the pyrrolidinophosphole liga
Please cite this article in press as: K. Fourmy, et al., Gold(I) comp
activity, Comptes Rendus Chimie (2016), http://dx.doi.org/10.1016the introduction of a nitrogen moiety was envisioned either
in the X-ligand or in the L-ligand structures. [Au(TPP)NTf2] 5
was easily obtained as an air-stable compound but the
replacement of the chloride ligand by the bis(tri-
ﬂuoromethanesulfonyl)imidate NTf2 did not lead to any
improvement of the in vitro antiplasmodial activity: both
[Au(TPP)NTf2] 5 and [Au(TPP)Cl] 3 showed a moderatend L6 and its corresponding gold(I) complex 6.
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Table 1
In vitro antiplasmodial activities of gold(I) complexes on the P. falciparum
strain FcM29-Cameroona and on FcB1-Colombiab; [n: number of inde-
pendent experiments performed].
Compound IC50 (mM)
[Au(TMP)Cl] 1 13 ± 0.4 (n ¼ 4)a
[Au(DBP)Cl] 2 9.7 ± 2.0 (n ¼ 6)a
[Au(TPP)Cl] 3 24 ± 3.6 (n ¼ 7)a
[Au(DMP)Cl] 4 18.5 ± 3.0 (n ¼ 7)a
[Au(PPh3)Cl] 7.9 ± 0.5 (n ¼ 6)a
[Au(TPP)NTf2] 5 24 ± 1.8 (n ¼ 5)a
[Au(L6)Cl] 6 11.5 ± 0.9 (n ¼ 3)b
Chloroquine 0.494 ± 0.05 (n ¼ 4)a
0.187 ± 0.02 (n ¼ 3)b
Artemisinin 0.0127 ± 0.005 (n ¼ 4)a
0.005 ± 0.003 (n ¼ 3)b
K. Fourmy et al. / C. R. Chimie xxx (2016) 1e6 5activitywith an IC50 of 24mM(Table 1). In contrast,Hoffmann
andViseux [25] showed that good cytotoxic activities on two
cancer cell lines could be achieved with [Au(PPh3)NTf2]
while [Au(PPh3)Cl] was totally inactive on the same cells.
The introduction of an amine moiety in the L-ligand
backbone was achieved through the synthesis of the pyr-
rolidinophosphole ligand L6 and its corresponding gold(I)
complex [Au(L6)Cl] 6. Unfortunately, this new structural
modulation did not lead to any signiﬁcant improvement of
the biological activity: an IC50 of 11.5 mM was obtained on
the FcB1 strain for [Au(L6)Cl] 6, which is in the same range
as the IC50 of 13 mM obtained on the FcM29-Cameroon
strain for the analogous [Au(TMP)Cl] 1.
Finally, the six prepared gold(I) phosphole complexes
1e6 showed IC50 in the range 9.7e24 mM against P. falcip-
arum chloroquino-resistant strains.
3. Conclusions
In summary, a series of gold(I) complexes featuring a
monophosphole ligand has been prepared, fully charac-
terized and evaluated by the in vitro antiplasmodial refer-
ence assay.
Whatever the modulations achieved on the phosphole
skeleton or on the X-ligand, the prepared gold(I) phosphole
complexes showed moderate IC50 in the range 9.7e24 mM
against chloroquine-resistant strains of P. falciparum, which
precludes such as their development as antimalarial com-
pounds. The weak antiplasmodial activities of our gold(I)
phosphole complexes may be due to their incapacity of
reaching their biological target; further studies are ongoing
in our laboratory to address this issue [31]. Moreover, other
biological activities are currently investigated for these
gold complexes such as anti-cancer properties [32].
4. Experimental section
4.1. General remarks
All commercially available reagents were used as
received. Silver salts were stored under argon in Schlenk
tubes. Unless otherwise stated, all reactionswere run under
argon using Schlenk techniques. Dichloromethane, THF,
Et2O and pentane were dried under nitrogen using a sol-
vent puriﬁcation system (SPS). NMR spectra were recordedPlease cite this article in press as: K. Fourmy, et al., Gold(I) comp
activity, Comptes Rendus Chimie (2016), http://dx.doi.org/10.1016at 25 C on a Bruker Avance 500, 400 Ultrashield, a DPX300
or Fourier 300 Ultrashield apparatus. 1H NMR and 13C{1H}
NMR chemical shifts are referenced to the solvent signal.
31P{1H} NMR chemical shifts are referenced to an external
standard (85% aqueous H3PO4). Multiplicity is as follows:
s ¼ singlet, d ¼ doublet, and t ¼ triplet. ESI analyses were
performed on an API-365 spectrometer.
4.2. Synthesis of gold(I) complexes
4.2.1. Synthesis of [Au(TPP)NTf2] 5
The gold chloride complex [Au(TPP)Cl] 3 (0.2mmol) was
dissolved in CH2Cl2 (5 mL), and AgNTf2 (78 mg, 0.2 mmol)
was added resulting in the instantaneous formation of the
expected silver chloride precipitate. The mixture was stir-
red for an additional 15 min and ﬁltrated over Celite to
remove the silver chloride salts. After evaporation to dry-
ness and drying in a vacuum, complex 5 was obtained
quantitatively as a yellow solid. NMR data were in agree-
ment with those reported in the literature [24].
4.2.2. Synthesis of [Au(L6)Cl] 6
In a ﬂamed Schlenk, (R)-2-(diphenylmethyl)pyrrolidine
6b (86.15 mg, 0.363 mmol, 1 equiv) was diluted in 5 mL of
THFand cooled down to78 C. n-BuLi (226 mL, 0.363mmol,
1 equiv) was added dropwise. The solution turned orange.
After 30 min, a solution of TMP-CN 6a [26](60 mg,
0.363 mmol, 1 equiv) in 5 mL of THF was added dropwise.
The solutionwas left for 1 h at 78 C and allowed to warm
up to room temperature for over 2 h. The dark red solution
was then concentrated to dryness and extracted with
approximately 3  8 mL of Et2O. These extracts were then
concentratedagain todryness andextractedwith38mLof
pentane. Ligand L6 was ﬁnally obtained as a yellow oil and
was used for the complexation step without further puriﬁ-
cation (31P{1H} NMR (121.5 MHz, Told8) d 62.5).
To a solution of the ligand L6 (80 mg, 0.21 mmol,
1.4 equiv) in dry CH2Cl2 (5 mL), was added chlor-
o(dimethylsulﬁde)gold(I) [Au(SMe2)Cl] (45 mg, 0.15 mmol,
1 equiv) and the reaction mixture was stirred at room
temperature for 2 h. After concentration and precipitation
with pentane, a white solid was obtained in 48% yield from
6a.
31P{1H} NMR (121.5 MHz, CDCl3) d 79.6; 1H NMR
(300 MHz, CDCl3) d 7.49e7.21 (m, 10Har), 4.76 (m, 1H, HC-
N), 3.9 (d, 3JHeH ¼ 12 Hz, 1H, HC(Ph)2), 2.88 (m, 1H,
HeCHeN), 2.61 (m,1H,H′eCHeN), 1.9 (m, 4H, CH2), 1.86 (s,
3H, CH3), 1.82 (s, 3H, CH3), 1.79 (d, 3H, CH3, 3JHeP ¼ 12 Hz),
1.30 (d, 3H, CH3, 3JHeP ¼ 12 Hz).
13C{1H} NMR (75MHz, CDCl3) d 146.3 (C),145.9 (C),145.4
(C), 142.3 (C), 142.2 (C), 129.3 (CH), 129.2 (CH), 128.8 (CH),
126.8 (CH), 126.7 (CH), 125.6 (CH), 69.2 (CH, 2JCeP ¼ 7.5 Hz),
56.3 (CH2), 45.6 (CH), 30.9 (CH2), 24.7 (CH2), 13.6 (CH3), 11.0
(CH3, 2JCeP ¼ 18 Hz), 10.7 (CH3, 2JCeP ¼ 18 Hz).
Mass: ESI m/z calc. for C25H30AuClNP: 607.1, found:
572.1 [MCl].
4.3. Crystal structure determination
Diffraction data were collected at low temperature (180
K) on a Bruker Kappa Apex II using graphite-lexes bearing phosphole ligands: Synthesis and antimalarial
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K. Fourmy et al. / C. R. Chimie xxx (2016) 1e66monochromated Mo Ka radiation (l ¼ 0.71073 Å). The
diffractometer is equipped with an Oxford Cryosystems
Cryostream cooler device. The structures were solved by
direct methods SHELXS-97. All non-hydrogen atoms were
reﬁned anisotropically by means of least-squares pro-
cedures on F2 with the aid of the program SHELXL-97 [33].
Crystallographic data have been deposited at the Cam-
bridge Crystallographic Data Centre with deposition
numbers CCDC 1039395 and 1039396.
4.4. Biological evaluation: P. falciparum cultures and
antiplasmodial assays
The chloroquine-resistant P. falciparum strains FcM29-
Cameroon and FcB1-Colombia were in vitro continuously
cultured as already published [34,35]. The standard radio-
isotopic micro-method [35,36] was used to evaluate the
antiplasmodial activity of these complexes. Parasite cul-
tures were incubated with various concentrations of the
drug for 48 h. Themolecules tested were ﬁrstly dissolved in
dimethyl sulfoxide and then in RPMI 1640 (Gibco Invi-
trogen, USA) to obtain solutions ranging from 50 mg/mL to
50 ng/mL. In parallel, both antimalarial compounds chlo-
roquine (Bufa, Holland) and artemisinin (TCI, France) were
tested and used as controls. Results obtained with standard
antiplasmodial drugs chloroquine and artemisinin for both
strains FcM29-Cameroon (IC50 CQ ¼ 494 nM; IC50
ART¼ 12.7 nM) and FcB1-Colombia (IC50 CQ¼ 187 nM; IC50
ART ¼ 5 nM) are in accordance with the literature [35].
Parasite growth was estimated by [3H] hypoxanthine
incorporation (PerkinElmer, France). The IC50 values re-
ported are the mean of at least three independent experi-
ments (the number of independent experiments
performed is reported in Table 1).
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